LBA
BCAX

Letko, Brosseau & Associates’s Bicara Therapeutics BCAX Stock Holding History

Letko, Brosseau & Associates’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Hold
11,175
– – ﹤0.01% 91
2026
Q1 		$222K Hold
11,175
– – ﹤0.01% 89
2025
Q4 		$188K Buy
+11,175
New +$191K ﹤0.01% 92

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Letko, Brosseau & Associates's BCAX Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 11,175 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #91.

Letko, Brosseau & Associates first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Letko, Brosseau & Associates held 11,175 shares of Bicara Therapeutics worth $332K as of Q2 2026.
  • Letko, Brosseau & Associates left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #91 holding.
  • Letko, Brosseau & Associates first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.